close
Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2002 Oct;57(Suppl 2):ii24–ii30.

PNEUMOCOCCAL AND INFLUENZA VACCINATION: CURRENT SITUATION AND FUTURE PROSPECTS

F Horwood, J Macfarlane
PMCID: PMC1766003  PMID: 12364707

Full Text

The Full Text of this article is available as a PDF (143.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed A. E., Nicholson K. G., Nguyen-Van-Tam J. S. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet. 1995 Sep 2;346(8975):591–595. doi: 10.1016/s0140-6736(95)91434-x. [DOI] [PubMed] [Google Scholar]
  2. Atmar R. L., Bloom K., Keitel W., Couch R. B., Greenberg S. B. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine. 1990 Jun;8(3):217–224. doi: 10.1016/0264-410x(90)90049-r. [DOI] [PubMed] [Google Scholar]
  3. Belshe R. B., Mendelman P. M., Treanor J., King J., Gruber W. C., Piedra P., Bernstein D. I., Hayden F. G., Kotloff K., Zangwill K. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14;338(20):1405–1412. doi: 10.1056/NEJM199805143382002. [DOI] [PubMed] [Google Scholar]
  4. Beyer W. E., Palache A. M., Baljet M., Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine. 1989 Oct;7(5):385–394. doi: 10.1016/0264-410x(89)90150-3. [DOI] [PubMed] [Google Scholar]
  5. Bosarge J. R., Watt J. M., McDaniel D. O., Swiatlo E., McDaniel L. S. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect Immun. 2001 Sep;69(9):5456–5463. doi: 10.1128/IAI.69.9.5456-5463.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boyce T. G., Poland G. A. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother. 2000 May;54(4):210–218. doi: 10.1016/S0753-3322(00)89027-7. [DOI] [PubMed] [Google Scholar]
  7. Briles D. E., Forman C., Horowitz J. C., Volanakis J. E., Benjamin W. H., Jr, McDaniel L. S., Eldridge J., Brooks J. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun. 1989 May;57(5):1457–1464. doi: 10.1128/iai.57.5.1457-1464.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Briles D. E., Yother J., McDaniel L. S. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 2):S372–S374. doi: 10.1093/cid/10.supplement_2.s372. [DOI] [PubMed] [Google Scholar]
  9. Chen D., Periwal S. B., Larrivee K., Zuleger C., Erickson C. A., Endres R. L., Payne L. G. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol. 2001 Sep;75(17):7956–7965. doi: 10.1128/JVI.75.17.7956-7965.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Christenson B., Lundbergh P., Hedlund J., Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001 Mar 31;357(9261):1008–1011. doi: 10.1016/S0140-6736(00)04237-9. [DOI] [PubMed] [Google Scholar]
  11. Cox N. J., Subbarao K. Influenza. Lancet. 1999 Oct 9;354(9186):1277–1282. doi: 10.1016/S0140-6736(99)01241-6. [DOI] [PubMed] [Google Scholar]
  12. Crain M. J., Waltman W. D., 2nd, Turner J. S., Yother J., Talkington D. F., McDaniel L. S., Gray B. M., Briles D. E. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun. 1990 Oct;58(10):3293–3299. doi: 10.1128/iai.58.10.3293-3299.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Davidson M., Bulkow L. R., Grabman J., Parkinson A. J., Chamblee C., Williams W. W., Lanier A. P., Schiffman G. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med. 1994 Oct 10;154(19):2209–2214. [PubMed] [Google Scholar]
  14. Edwards K. M., Dupont W. D., Westrich M. K., Plummer W. D., Jr, Palmer P. S., Wright P. F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994 Jan;169(1):68–76. doi: 10.1093/infdis/169.1.68. [DOI] [PubMed] [Google Scholar]
  15. Fedson D. S., Wajda A., Nicol J. P., Hammond G. W., Kaiser D. L., Roos L. L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA. 1993 Oct 27;270(16):1956–1961. [PubMed] [Google Scholar]
  16. Fine M. J., Smith M. A., Carson C. A., Meffe F., Sankey S. S., Weissfeld L. A., Detsky A. S., Kapoor W. N. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med. 1994 Dec 12;154(23):2666–2677. doi: 10.1001/archinte.1994.00420230051007. [DOI] [PubMed] [Google Scholar]
  17. Gorse G. J., Belshe R. B., Munn N. J. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest. 1991 Oct;100(4):977–984. doi: 10.1378/chest.100.4.977. [DOI] [PubMed] [Google Scholar]
  18. Govaert T. M., Thijs C. T., Masurel N., Sprenger M. J., Dinant G. J., Knottnerus J. A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994 Dec 7;272(21):1661–1665. [PubMed] [Google Scholar]
  19. HEIDELBERGER M., DILAPI M. M., SIEGEL M., WALTER A. W. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J Immunol. 1950 Nov;65(5):535–541. [PubMed] [Google Scholar]
  20. Hayden F. G., Atmar R. L., Schilling M., Johnson C., Poretz D., Paar D., Huson L., Ward P., Mills R. G. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 Oct 28;341(18):1336–1343. doi: 10.1056/NEJM199910283411802. [DOI] [PubMed] [Google Scholar]
  21. Hayden F. G., Gubareva L. V., Monto A. S., Klein T. C., Elliot M. J., Hammond J. M., Sharp S. J., Ossi M. J., Zanamivir Family Study Group Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000 Nov 2;343(18):1282–1289. doi: 10.1056/NEJM200011023431801. [DOI] [PubMed] [Google Scholar]
  22. Hayden F. G., Osterhaus A. D., Treanor J. J., Fleming D. M., Aoki F. Y., Nicholson K. G., Bohnen A. M., Hirst H. M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997 Sep 25;337(13):874–880. doi: 10.1056/NEJM199709253371302. [DOI] [PubMed] [Google Scholar]
  23. Hedlund J. U., Kalin M. E., Ortqvist A. B., Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med. 1994 Sep 12;154(17):1961–1965. [PubMed] [Google Scholar]
  24. Kaiser L., Henry D., Flack N. P., Keene O., Hayden F. G. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis. 2000 Mar;30(3):587–589. doi: 10.1086/313696. [DOI] [PubMed] [Google Scholar]
  25. Koivula I., Stén M., Leinonen M., Mäkelä P. H. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997 Oct;103(4):281–290. doi: 10.1016/s0002-9343(97)00149-6. [DOI] [PubMed] [Google Scholar]
  26. Maassab H. F. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol. 1969 Mar;102(3):728–732. [PubMed] [Google Scholar]
  27. McDaniel L. S., Ralph B. A., McDaniel D. O., Briles D. E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog. 1994 Nov;17(5):323–337. doi: 10.1006/mpat.1994.1078. [DOI] [PubMed] [Google Scholar]
  28. McDaniel L. S., Sheffield J. S., Delucchi P., Briles D. E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun. 1991 Jan;59(1):222–228. doi: 10.1128/iai.59.1.222-228.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Monto A. S., Robinson D. P., Herlocher M. L., Hinson J. M., Jr, Elliott M. J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999 Jul 7;282(1):31–35. doi: 10.1001/jama.282.1.31. [DOI] [PubMed] [Google Scholar]
  30. Mossad S. B. Prophylactic and symptomatic treatment of influenza. Current and developing options. Postgrad Med. 2001 Jan;109(1):97–24. doi: 10.3810/pgm.2001.01.827. [DOI] [PubMed] [Google Scholar]
  31. Mufson M. A., Krause H. E., Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med. 1983 Jun;173(2):270–275. doi: 10.3181/00379727-173-41643. [DOI] [PubMed] [Google Scholar]
  32. Musher D. M., Groover J. E., Rowland J. M., Watson D. A., Struewing J. B., Baughn R. E., Mufson M. A. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis. 1993 Jul;17(1):66–73. doi: 10.1093/clinids/17.1.66. [DOI] [PubMed] [Google Scholar]
  33. Nabors G. S., Braun P. A., Herrmann D. J., Heise M. L., Pyle D. J., Gravenstein S., Schilling M., Ferguson L. M., Hollingshead S. K., Briles D. E. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine. 2000 Mar 6;18(17):1743–1754. doi: 10.1016/s0264-410x(99)00530-7. [DOI] [PubMed] [Google Scholar]
  34. Nichol K. L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999 Mar 2;130(5):397–403. doi: 10.7326/0003-4819-130-5-199903020-00003. [DOI] [PubMed] [Google Scholar]
  35. Nichol K. L., Baken L., Wuorenma J., Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999 Nov 8;159(20):2437–2442. doi: 10.1001/archinte.159.20.2437. [DOI] [PubMed] [Google Scholar]
  36. Nichol K. L. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine. 2001 Aug 14;19(31):4373–4377. doi: 10.1016/s0264-410x(01)00143-8. [DOI] [PubMed] [Google Scholar]
  37. Nichol K. L., Margolis K. L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994 Sep 22;331(12):778–784. doi: 10.1056/NEJM199409223311206. [DOI] [PubMed] [Google Scholar]
  38. Nichol K. L., Mendelman P. M., Mallon K. P., Jackson L. A., Gorse G. J., Belshe R. B., Glezen W. P., Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999 Jul 14;282(2):137–144. doi: 10.1001/jama.282.2.137. [DOI] [PubMed] [Google Scholar]
  39. Nicholson K. G. Socioeconomics of influenza and influenza vaccination in Europe. Pharmacoeconomics. 1996;9 (Suppl 3):75–78. doi: 10.2165/00019053-199600093-00017. [DOI] [PubMed] [Google Scholar]
  40. Ortqvist A., Hedlund J., Burman L. A., Elbel E., Höfer M., Leinonen M., Lindblad I., Sundelöf B., Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998 Feb 7;351(9100):399–403. doi: 10.1016/s0140-6736(97)07358-3. [DOI] [PubMed] [Google Scholar]
  41. Poland G. A., Couch R. Intranasal influenza vaccine: adding to the armamentarium for influenza control. JAMA. 1999 Jul 14;282(2):182–184. doi: 10.1001/jama.282.2.182. [DOI] [PubMed] [Google Scholar]
  42. Rudenko L. G., Arden N. H., Grigorieva E., Naychin A., Rekstin A., Klimov A. I., Donina S., Desheva J., Holman R. C., DeGuzman A. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine. 2000 Sep 15;19(2-3):308–318. doi: 10.1016/s0264-410x(00)00153-5. [DOI] [PubMed] [Google Scholar]
  43. Rudenko L. G., Slepushkin A. N., Monto A. S., Kendal A. P., Grigorieva E. P., Burtseva E. P., Rekstin A. R., Beljaev A. L., Bragina V. E., Cox N. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 1993 Oct;168(4):881–887. doi: 10.1093/infdis/168.4.881. [DOI] [PubMed] [Google Scholar]
  44. Shapiro E. D., Berg A. T., Austrian R., Schroeder D., Parcells V., Margolis A., Adair R. K., Clemens J. D. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991 Nov 21;325(21):1453–1460. doi: 10.1056/NEJM199111213252101. [DOI] [PubMed] [Google Scholar]
  45. Shapiro E. D., Berg A. T., Austrian R., Schroeder D., Parcells V., Margolis A., Adair R. K., Clemens J. D. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991 Nov 21;325(21):1453–1460. doi: 10.1056/NEJM199111213252101. [DOI] [PubMed] [Google Scholar]
  46. Swierkosz E. M., Newman F. K., Anderson E. L., Nugent S. L., Mills G. B., Belshe R. B. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis. 1994 May;169(5):1121–1124. doi: 10.1093/infdis/169.5.1121. [DOI] [PubMed] [Google Scholar]
  47. Treanor J. J., Mattison H. R., Dumyati G., Yinnon A., Erb S., O'Brien D., Dolin R., Betts R. F. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med. 1992 Oct 15;117(8):625–633. doi: 10.7326/0003-4819-117-8-625. [DOI] [PubMed] [Google Scholar]
  48. Treanor J., Dumyati G., O'Brien D., Riley M. A., Riley G., Erb S., Betts R. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J Infect Dis. 1994 Feb;169(2):402–407. doi: 10.1093/infdis/169.2.402. [DOI] [PubMed] [Google Scholar]
  49. Whitney C. G., Schaffner W., Butler J. C. Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis. 2001 Jul 30;33(5):662–675. doi: 10.1086/322676. [DOI] [PubMed] [Google Scholar]
  50. Wizemann T. M., Heinrichs J. H., Adamou J. E., Erwin A. L., Kunsch C., Choi G. H., Barash S. C., Rosen C. A., Masure H. R., Tuomanen E. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun. 2001 Mar;69(3):1593–1598. doi: 10.1128/IAI.69.3.1593-1598.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wu H. Y., Nahm M. H., Guo Y., Russell M. W., Briles D. E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis. 1997 Apr;175(4):839–846. doi: 10.1086/513980. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES